期刊文献+

重症感染降阶梯抗菌治疗策略的修正刍议 被引量:12

原文传递
导出
摘要 一、降阶梯抗感染治疗策略的提出与争议感染治疗的传统理念是保留最有效药物以备后用,实践中药物选择便是从“低”到“高”、从单药到联合.这正契合了减少用药以避免耐药选择性压力的抗生素使用原则.然而自20世纪90年代起耐药问题凸显,一些危重症临床学家发现,住ICU重症肺炎、血流感染等患者初始抗菌治疗不足(inadequate)组病死率24.7% ~ 91.0%,显著高于治疗恰当(appropriate)组的15.6% ~ 33.0%.初始治疗不足亦包括治疗时间延误,在一组呼吸机相关肺炎(VAP)的研究发现,治疗延误(确立诊断后≥24 h)占30.8%,是最重要的死亡独立危险因素;VAP患者的基础疾病和肺部感染所致生理功能损害的严重程度等独立危险因素是无法纠正的,唯有抗菌治疗是应当,而且可以改进的.在肺炎等待病原学检测结果后修正和给予足够抗生素治疗,与早期足够经验性治疗比较,并不能改善结局。
作者 何礼贤
出处 《中华内科杂志》 CAS CSCD 北大核心 2015年第10期827-830,共4页 Chinese Journal of Internal Medicine
  • 相关文献

参考文献35

  • 1Alvarez-LermaF. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group[J]. Intensive Care Med, 1996, 22(5):387–394.
  • 2LunaCM, VujacichP, NiedermanMS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia[J]. Chest, 1997, 111(3):676–685.
  • 3RelloJ, GallegoM, MariscalD, et al. The value of routine microbial investigation in ventilator-associated pneumonia[J]. Am J Respir Crit Care Med, 1997, 156(1):196–200.
  • 4KollefMH, WardS. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia[J]. Chest, 1998, 113(2):412–420.
  • 5IbrahimEH, ShermanG, WardS, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting[J]. Chest, 2000, 118(1):146–155.
  • 6IreguiM, WardS, ShermanG, et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia[J]. Chest, 2002, 122(1):262–268.
  • 7KollefMH, ShermanG, WardS, et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients[J]. Chest, 1999, 115(2):462–474.
  • 8KollefMH. Hospital-acquired pneumonia and de-escalation of antimicrobial treatment[J]. Crit Care Med, 2001, 29(7):1473–1475.
  • 9RelloJ, PaivaJA, BaraibarJ, et al. International conference for the development of consensus on the diagnosis and treatment of ventilator-associated pneumonia[J]. Chest, 2001, 120(3):955–970.
  • 10BodíM, ArdanuyC, OlonaM, et al. Therapy of ventilator-associated pneumonia: the Tarragona strategy[J]. Clin Microbiol Infect, 2001, 7(1):32–33.

二级参考文献25

  • 1Ibrahim EH,Ward S,Sherman G,et al.Experience with a clinical guideline for the treatment of ventilator-associated pneumonia.Crit Care Med,2001,29:1109-1115.
  • 2Wang H,Chen M; China Nosocomial Pathogens Resistance Surveillance Study Group.Surveillance for antimicrobial resistance among clinical isolates of gram-negative bacteria from intensive care unit patients in China,1996 to 2002.Diagn Microbiol Infect Dis,2005,51:201-208.
  • 3Bechicchio GV,Baquero F,Hsueh PR,et al.In vitro susceptibilities of Escherichia coli isolated from patients with intraabdominal infections worldwide in 2002-2004:results from SMART (Study for Monitoring Antimicrobial Resistance Trends).Surg Infect (Larchmt),2006,7:537-545.
  • 4Tian SF,Chert BY,Chu YZ,et al.Prevalence of rectal carriage of extended-spectrum beta-lactamase-preducing Escherichia coli among elderly people in community settings in China.Can J Microbiol,2008,54:781-785.
  • 5Colodner R,Rock W,Chazan B,et al.Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients.Eur J Clin Microbial Infect Dis,2004,23:163-167.
  • 6Paterson DL,Ko WC,Von Gottherg A,et al.International prospective study of Klebsiella pneumoniae bacteremia:implications of extended-spectrum beta-lactamase production in nosocomial Infections.Ann Intern Med,2004,140:26-32.
  • 7Trouillet JL,Chastre J,Vuagnat A,et al.Ventilator-associated pneumonia caused by potentially drug-resistant bacteria.Am J Respir Crit Care Med,1998,157:531-539.
  • 8Shorr AF,Sherner JH,Jackson WL,et al.Invasive approaches to the diagnosis of ventilator-associated pneumonia:a meta-analysis.Crit Care Meal,2005,33:46-53.
  • 9Arias CA. Murray BE. Antibiotic-resistant bugs in the 21st century-a clinical super-challenge[J].N Engl J Med. 2009. 360(5): 439-443.
  • 10Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing[S]. Twentyfourth informational supplement. 2014. M100-S24 Vol 34 No. 1.

共引文献657

同被引文献105

引证文献12

二级引证文献110

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部